Sierra Oncology Acquires Gilead’s Momelotinib to Treat Myelofibrosis for ~$198M
Sierra Oncology Acquires Gilead’s Momelotinib to Treat Myelofibrosis for ~$198M
Shots:
- Sierra will pay $3M upfront and ~$195M milestone payments to Gilead and additional royalties from mid-teen-to-high-twenties on net sales
- Sierra will continue all currently ongoing clinical studies with Momelotinib following a transition period
- Momelotinib (a JAK 1/2 and ACVR1 Inhibitor) is in Phase III, has being administered to ~1200 patients, since 2009, and is expected to get patent exclusivity in EU and U.S. till 2033 and 2035 respectively
Click here to read full press release/ article | Ref: Sierraoncology | Image: Sierra oncology